Is obesity a contraindication for simultaneous bilateral total knee arthroplasty? A prospective case-control study
Sanjay Agarwala1, Yash Santosh Wagh2, Mayank Vijayvargiya3
1Chief of Orthopaedics and Director Professional Services, P.D Hinduja Hospital and Medical Research Centre, Mumbai, India.
SICOT-J
|October 30, 2020
Summary
Simultaneous bilateral total knee arthroplasty (TKA) shows comparable mid-term functional outcomes and complication rates in obese versus non-obese Indian patients. This study found similar recovery and Oxford knee scores after 3 months for both groups.
Area of Science:
- Orthopedic Surgery
- Biomedical Engineering
- Reconstructive Surgery
Background:
- Total knee arthroplasty (TKA) is a common procedure for knee arthritis.
- Limited data exists comparing outcomes of simultaneous bilateral TKA in obese versus non-obese Indian populations.
- Obesity is a growing concern impacting surgical outcomes.
Purpose of the Study:
- To evaluate and compare functional outcomes and complication rates of simultaneous bilateral TKA in obese versus non-obese Indian patients.
- To assess the impact of obesity on recovery and mid-term results after bilateral knee replacement.
Main Methods:
- Patients were stratified into obese (BMI > 30) and non-obese (BMI < 30) groups.
- All patients underwent simultaneous bilateral TKA using identical implants and surgical techniques.
- Functional outcomes (Oxford knee score) and complications were assessed at 6 weeks, 3 months, and 1 year post-surgery.
Main Results:
- No significant differences were observed in post-operative hemoglobin drop, ICU stays, hospital length of stay, walking time, or stair climbing time between groups.
- While non-obese patients had better scores at 6 weeks, Oxford knee scores were similar at 3 months, 1 year, and last follow-up for both groups.
- Complication rates, implant loosening, and radiolucency were comparable, with no statistically significant differences.
Conclusions:
- Simultaneous bilateral TKA yields comparable mid-term functional results in obese Indian patients compared to their non-obese counterparts.
- Obesity does not appear to significantly compromise the outcomes of simultaneous bilateral TKA in the mid-term follow-up period.
Related Concept Videos
Drug Dosing: Obese Patients
106
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
106
Obesity
968
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
968
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
127
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
127
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
89
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
89


